Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Adial Pharmaceuticals ( (ADIL) ) just unveiled an announcement.
On April 7, 2026, Adial Pharmaceuticals’ Compensation Committee approved grants of restricted stock awards to key executives, including 37,985 shares to Chief Executive Officer and Director Cary Claiborne, 17,325 shares to Chief Financial Officer Vinay Shah, and 26,510 shares to Chief Operating Officer and Director Tony Goodman, with allocations reflecting both their executive and board roles. The committee also granted 9,185 restricted shares each to directors Kevin Schuyler and Robertson H. Gilliland and stock options for 9,185 shares to director Kermit Anderson at an exercise price of $1.64, with all awards vesting after one year or upon a change of control, and the Board concurrently approved a standardized restricted stock award agreement to govern these grants, signaling a structured approach to equity-based compensation and alignment of leadership incentives with shareholder interests.
The most recent analyst rating on (ADIL) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Adial Pharmaceuticals stock, see the ADIL Stock Forecast page.
Spark’s Take on ADIL Stock
According to Spark, TipRanks’ AI Analyst, ADIL is a Neutral.
The score is held down primarily by weak financial performance (no revenue, sustained losses, and persistent cash burn) and bearish technicals (below key moving averages with negative MACD). Corporate events provide a modest offset via regained Nasdaq compliance and a potential European partnership, but valuation remains constrained by negative earnings.
To see Spark’s full report on ADIL stock, click here.
More about Adial Pharmaceuticals
Adial Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for addictions and related disorders. The company operates in the life sciences sector, targeting unmet medical needs with therapeutics aimed at improving outcomes for patients with substance use conditions and associated behavioral health issues.
Average Trading Volume: 91,682
Technical Sentiment Signal: Sell
Current Market Cap: $2.36M
Learn more about ADIL stock on TipRanks’ Stock Analysis page.